APA (7th ed.) Citation

Gentile, I., Viceconte, G., Cuccurullo, F., Pietroluongo, D., D’Agostino, A., Silvitelli, M., . . . Buonomo, A. R. Early combination of sotrovimab with nirmatrelvir/ritonavir or remdesivir is associated with low rate of persisting SARS CoV-2 infection in immunocompromised outpatients with mild-to-moderate COVID-19: A prospective single-centre study. Taylor & Francis Group.

Chicago Style (17th ed.) Citation

Gentile, I., et al. Early Combination of Sotrovimab with Nirmatrelvir/ritonavir or Remdesivir Is Associated with Low Rate of Persisting SARS CoV-2 Infection in Immunocompromised Outpatients with Mild-to-moderate COVID-19: A Prospective Single-centre Study. Taylor & Francis Group.

MLA (9th ed.) Citation

Gentile, I., et al. Early Combination of Sotrovimab with Nirmatrelvir/ritonavir or Remdesivir Is Associated with Low Rate of Persisting SARS CoV-2 Infection in Immunocompromised Outpatients with Mild-to-moderate COVID-19: A Prospective Single-centre Study. Taylor & Francis Group.